Desrazoxane is a cardioprotective agent used in preventing cardiovascular conditions during chemotherapy. A substance derived from EDTA, Desrazoxane chelates iron, is trustd to interfere with harmful substances inside cells, which may cause heart disease after using anthracyclines such as doxorubicin. However, exactly how Desrazoxane works in protecting the heart is not fully understood. It is available as Zinecard in the United States and Canada, and Cardiozane in the EU. This medicament is available in 250 mg and 500 mg vials for injection.
Desrazoxane is administered to prevent and reduce the severity of heart conditions which may occur during chemotherapy using anthracyclines, such as those used in the treatment of women suffering from metastatic breast cancer.
A Desrazoxane medicament marketed under brand name Totect or Savene has also been approved for use as a treatment of extravasation caused by anthracycline chemotherapy. Extravasation occurs during chemotherapy when anthracycline leaks out of the blood vessels and seeps to the skin.
The dose of Desrazoxane is dependent on the physical structure surface area of the patient as well as the doxorubicin dose being taken. The dose is usually measured in a 10:1 ratio with respect to the doxorubicin dose. Once the proper dose has been measured, the medicament can be administered directly into the vein via an IV push or through a quick infusion from an IV infusion bag. 30 minutes after the administration of Desrazoxane the IV injection of doxorubicin can be given.
Desrazoxane, is stable for about 6 hours after reconstitution if placed in an empty infusion bag at controlled room temperature ranging from 15° to 30°C (59° to 86°F), or placed in refrigeration at 2° to 8°C (36° to 46°F). It may also be diluted using a 0.9% sodium chloride injection, USP or using a 5.0% dextrose injection, USP. Dilute the medicament to a concentration between 1.3 to 5.0 mg/mL and store in empty IV infusion bags. Do not use leftover solutions.
One of the usual side effects experienced by those undergoing Desrazoxane treatment is pain or skin edema at the injection site. All blood counts can also be lower when taking Desrazoxane with chemotherapy compared to undergoing chemotherapy alone. Recovery periods for the blood counts do remain similar for both cases.
Other common side effects experienced include diarrhea, general discomfort, fever, loss of appetite and wamble. More serious side effects involve baldness, vomiting, skin edema of the throat and tongue, and severe allergic reactions that require immediate medical attention.
Desrazoxane should only be used in conjunction with anthracycline chemotherapy such as doxorubicin.
Certain chemotherapy may cause sterility in both men and women so consult your physician if you plan on having children. However, it has not yet been shown that Desrazoxane itself can cause sterility. If you trust that you might be pregnant, inform your physician about your condition before being given Desrazoxane.
You may also experience greater susceptibility to infection during treatment so consult with your physician before getting live virus vaccines to avoid complications.
Desrazoxane has the following structural formula:
• Molecular formula of Desrazoxane is C11H16N4O4
• Chemical IUPAC Name is 4-[1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione
• Molecular weight is 268.269 g/mol
• Desrazoxane available : 250mg injection and 500mg injection
©2007-2017 Medicalook.com All rights reserved